Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.

@article{Pommier2004CamptothecinsAT,
  title={Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.},
  author={Y. Pommier},
  journal={Current medicinal chemistry. Anti-cancer agents},
  year={2004},
  volume={4 5},
  pages={
          429-34
        }
}
  • Y. Pommier
  • Published 2004
  • Biology, Medicine
  • Current medicinal chemistry. Anti-cancer agents
  • Camptothecins selectively target topoisomerase I (Top1) by trapping the catalytic intermediate of the Top1-DNA reaction, the cleavage complex. Hence, camptothecins represent a paradigm for targeting macromolecular interactions. Instead of preventing the binding of the two macromolecules they target (Top1 and DNA), camptothecins slow down the dissociation of these macromolecules. The activity of camptothecins underlines the usefulness of screening for drugs that inhibit the dissociation of… CONTINUE READING
    Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine
    51

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 23 REFERENCES
    Bioorg Med Chem
    • 2004
    Curr Pharm Design
    • 2004
    Mol Cancer Ther
    • 2004
    Bioorg Med Chem Lett
    • 2003
    Cancer Res
    • 2003
    Crit Rev Oncol Hematol
    • 2003
    Curr Topics Med Chem
    • 2003
    Mutat Res
    • 2003